Noorik Biopharmaceuticals AG
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.noorik.com
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Endothelin Receptor Antagonism with Ambrisentan to Treat Hepatorenal Syndrome
- Conditions
- Acute Kidney InjuryHepatorenal SyndromeLiver CirrhosisAscites Hepatic
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 54
- Registration Number
- NCT06256432
- Locations
- 🇮🇳
Asian Institute of Gastroenterology (AIG), Hyderabad, Telangana, India
🇮🇳All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳Aster CMI Hospital, Bangalore, Karnataka, India
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 88
- Registration Number
- NCT04771000
- Locations
- 🇭🇷
General Hopital Zadar, Zadar, Croatia
🇭🇷University Hospital for Infectious Diseases Fran Mihaljevic, Zagreb, Croatia
🇪🇸Hospital Universitario de Cabueñes, Gijón, Asturias, Spain
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 19
- Registration Number
- NCT03827200
- Locations
- 🇪🇸
Hospital Clinic Barcelona, Barcelona, Catalunya, Spain
🇪🇸Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
🇪🇸Vall d'Hebron University Hospital, Barcelona, Spain